Mansuo Lu Shannon is our Chief Scientific Officer. With over 15 years of pharmaceutical and biotech experience, Mansuo brings executive leadership and scientific expertise across neurodegeneration and neurodevelopmental diseases. Mansuo joined Prevail from Eli Lilly and Company where she was the Senior Director of Neuroscience Discovery. At Eli Lilly, Mansuo led multiple programs from target identification to clinical candidate selection in the areas of tau and synuclein, aiming to deliver novel disease-modifying therapies for Alzheimer’s disease and Parkinson’s disease. Prior to Eli Lilly, Mansuo was a group leader with Chugai/Roche and Merck. Mansuo’s postdoctoral work on Fragile X syndrome led to the founding of biotech Afraxis.

Mansuo holds a Ph.D. in Molecular Biology from Princeton University and completed her postdoctoral research at the Massachusetts Institute of Technology.